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AdultBackground: 21 million pregnant women worldwide (18%) are estimated to carry Group B Streptococcus
(GBS), which is a risk for invasive disease in newborns, pregnant women, and stillbirths.
Adults  60 years or with underlying health conditions are also vulnerable to invasive GBS disease.
We undertook systematic reviews on GBS organism characteristics including: capsular polysaccharide
(serotype), sequence type (multi-locus sequence types (MLST)), and virulence proteins. We synthesised
data by at-risk populations, to inform vaccine development.
Methods: We conducted systematic reviews and meta-analyses to estimate proportions of GBS serotypes
for at risk populations: maternal colonisation, invasive disease in pregnant women, stillbirths, infants 0–
90 days age, and older adults (60 years). We considered regional variation and time trends (2001–
2018). For these at-risk population groups, we summarised reported MLST and surface proteins.
Results: Based on 198 studies (29247isolates), 93–99% of GBS isolates were serotypes Ia, Ib, II, III, IV and
V. Regional variation is likely, but data gaps are apparent, even for maternal colonisation which has most
data. Serotype III dominates for infant invasive disease (60%) and GBS-associated stillbirths (41%). ST17
accounted for a high proportion of infant invasive disease (41%; 95%CI: 35–47) and was found almost
exclusively in serotype III strains, less present in maternal colonisation (9%; 95%CI:6–13),(4%; 95%CI:0–
11) infant colonisation, and adult invasive disease (4%, 95%CI:2–6). Percentages of strains with at least
one of alp 1, alp2/3, alpha C or Rib surface protein targets were 87% of maternal colonisation, 97% infant
colonisation, 93% infant disease and 99% adult invasive disease. At least one of three pilus islands proteins
were reported in all strains.
Discussion: A hexavalent vaccine (serotypes Ia, Ib, II, III, IV and V) might provide comprehensive cover for
all at-risk populations. Surveillance of circulating, disease-causing target proteins is useful to inform vac-
cines not targeting capsular polysaccharide. Addressing data gaps especially by world region and somesurface
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proteins as potential vaccine candidates, Vaccinat-risk populations (notably stillbirths) is fundamental to evidence-based decision-making during vac-
cine design.
 2020 The Authors. Published by Elsevier Ltd. This is an open access article under theCCBY license (http://
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Deaths for children before their fifth birthday have reduced
from an estimated 12.6 million child deaths in 1990 to 5.3 million
deaths in 2017 [1]. This decline is in part attributed to high cover-
age of childhood immunisations [2], although infectious causes
still account for at least a quarter of under-five child deaths. Almost
half of child deaths worldwide occur in the neonatal period [2], and
approximately two thirds within the first three months of life, so
more attention is required to meet Sustainable Development Goals
(SDG) by 2030 [3]. Hence there is more urgency in addressing the
confluence of neonatal deaths and infections, with maternal immu-
nisation as one strategy [4].
Group B Streptococcus (GBS) or Streptococcus agalactiae is a
Gram-positive bacterium, commonly colonising the gastrointesti-
nal tract. Worldwide around 18% of pregnant women are colonised
by GBS – totalling over 21 million women each year [5]. Colonisa-
tion carries risk of invasive GBS disease in babies (before or after
birth), and pregnant/postnatal women. Ascending GBS infections
in pregnant women can lead to stillbirth or preterm birth [6–10].
GBS invasive disease burden was estimated to be 319,000 infants
in 2015 [uncertainty range (UR), 119000–417000], resulting in
90,000 (UR 36000–169000) deaths, at least 57,000 (UR 12000–
104000) fetal infections/stillbirth, and up to 3.5 million preterm
births [11]. Maternal invasive GBS disease during pregnancy/post-
natally affected at least 33,000 (UR 13000–52000) women [11].
GBS disease in the elderly was not included in previous burden
estimates, but is increasingly recognised public health issue, caus-
ing morbidity and mortality [12–14].
Intrapartum antibiotic prophylaxis (IAP) to reduce early-onset
GBS disease (EOGBS), and in the United States of America (USA),
implementation since 1990 has been associated with > 80% reduc-
tion in EOGBS incidence [15]. However, most low and lower-
middle-income countries (LMIC) do not have a specific IAP policy
[16], and scale-up is likely to be challenging [17]. Additionally,ul, K. N. To et al., Systematic re
e, https://doi.org/10.1016/j.vacIAP has no effect on reducing late-onset GBS disease (LOGBS)
[13], and would not be expected to prevent GBS associated still-
birth or preterm birth, due to IAP administration is given after
onset of labor and/or rupture of membranes. In contrast, an effec-
tive GBS vaccine could prevent invasive GBS disease across all at-
risk population groups, including mother, fetus, infant, and the
elderly or immunocompromised [11].
Several GBS vaccine candidates are in development, including
multivalent GBS bacterial capsular polysaccharide (CPS) -CRM197
conjugate vaccines [18], CPS-protein conjugates vaccines [19],
and multivalent adjuvanted protein vaccines (NCT03807245). Pla-
cental transfer of anti-CPS specific GBS antibodies from the mother
to the fetus reduces the risk of invasive GBS disease with evidence
of protection against both EOGBS and LOGBS [20]. Multivalent CPS-
protein conjugate vaccines induce an increased CPS-specific IgG
response [21]. Since capsular-type switching is possible [22], there
is also interest in developing GBS protein-based vaccines, and
protein-based vaccines are undergoing preclinical studies [23] or
Phase I/II clinical trials (NCT03807245).
GBS isolates are classified by their CPS into ten serotypes: Ia, Ib,
II-IX. Strains are assigned to a sequence type (ST), through multi-
locus sequence typing (MLST), based on allelic variation of seven
housekeeping genes [24] further grouping similar allelic profiles
into clonal complexes (CC). Molecular techniques, including MLST
and whole-genome sequencing (WGS), have enabled better charac-
terisation of GBS, and highlighted that different capsular serotypes
are present within the same ST. The latter is especially important
for capsule polysaccharide-based vaccines as certain sequence
types have been more associated with GBS human disease, such
as ST17. A strong association between ST17 and severe neonatal
and young infant disease has been demonstrated [25–27]. Five
major clonal complexes in humans (CC1, CC10, CC17, CC19, and
CC23) are associated with colonisation and invasiveness of GBS
[28–30]. GBS strains can also be classified on the basis of surface
proteins, such as Alp family proteins, serine-rich repeat proteins,view of Group B Streptococcal capsular types, sequence types and surface
cine.2020.08.052
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and pilus island proteins have also been associated with invasive-
ness of GBS strains [32–35].
Development of GBS vaccines should be informed by evidence
from all over the world, considering all the relevant at-risk popula-
tions, and data not just on serotype distribution, but also strain
types and conserved protein targets. This study aims to inform
GBS vaccine design, based on systematic reviews and meta-
analyses regarding GBS serotypes, considering geographical varia-
tion and time trends. We update literature searches [36] regarding
serotype data for 1). maternal colonisation, 2). maternal invasive
disease and 3). infant invasive disease. Additionally, we expand
the previously covered at-risk populations to include 4). stillbirths
and 5). disease in adults over 60 years old. We also expanded the
searches remit from serotypes alone to cover sequence types and
specific surface protein genes.
2. Methods
2.1. Case definitions
Definitions for maternal GBS colonisation, invasive GBS disease,
EOGBS, LOGBS, and maternal invasive GBS disease, have been
detailed previously [5,9,36–38] (supplementary Table S1). For still-
birth, we used the World Health Organisation definition for inter-
national comparison and reporting (birth of a fetus with no signs of
life at  28 weeks’ gestation or weighing 1000 g), and the Interna-
tional Classification of Disease definition (birth of a fetus with no
signs of life at 22 weeks or more gestation or weighing > 500 g)
[39]. GBS invasive disease in older adults was defined after 60 years
of age.
2.2. Search strategy and inclusion criteria
We performed systematic literature searches in Medline,
Embase, Scopus, the World Health Organisation Library Informa-
tion System (WHOLIS), and Literature in Health Sciences in Latin
America and the Caribbean (LILACS). Searches were limited to
humans with no language restrictions. All searches were to March
2019. For maternal colonisation and infant GBS disease, the litera-
ture searches were from 2017 to current, updating previously con-
ducted literature reviews [5,37]. All searches included ‘‘Group B
Streptococcus” or ‘‘Streptococcus agalactiae”, combined with
‘‘serotype” or with ‘‘sequencing” or ‘‘MLST”. Specific search terms
per database are in supplementary Table S2. Medical subject head-
ing (MeSH) terms were used where possible. Snowballing identi-
fied additional studies. We included studies reporting serotypes,
sequence types and protein expression either from observational
studies or pooled laboratory samples, and presented proportions
among cases. Inclusion and exclusion criteria are detailed in sup-
plementary Table S3.
Database searches, screening for duplicates and titles for eligi-
bility, and selection of abstracts were performed by FBJ for sero-
type data updates and KT, CCA, KLD and EJ for MLST/virulence
factors. Assessment of full-length articles, and data extraction,
was done by two independent investigators, FBJ and PP for sero-
type data and KT, KLD and EJ for MLST/virulence factors. If there
was discrepancy between two reviewers, a third investigator made
the final decision.
2.3. Data abstraction
Data were extracted into standardised Excel forms including:
year of study, country, study site, study design, definitions usedPlease cite this article as: F. Bianchi-Jassir, P. Paul, K. N. To et al., Systematic re
proteins as potential vaccine candidates, Vaccine, https://doi.org/10.1016/j.vac(for invasive GBS disease or EOGBS/LOGBS or stillbirth), age of
patients from whom samples were taken, site of isolation (e.g. if
vaginal, rectal or both, for invasive disease whether isolate was
from blood or CSF cultures), and serotyping methods. United
Nations SDG region classification was used for world regions
[40]. For infant GBS disease studies, we abstracted serotype data
from cases with sepsis or bacteraemia and meningitis, when avail-
able. For MLST data we abstracted additionally infant colonisation,
and all adult invasive disease data (18yearsandolder). Reported
GBS genotypic data were summarised based on most common ST
and/or CC, number of isolates that were ST-17, detected virulence
genes, if WGS was done, and the related serotypes with CCs, and
presence of proteins of interest and pilus islands. Data collected
from previous review/meta-analyses were input as previously
reported.2.4. Analyses
Data were imported to STATA version 14 software (StataCorp
2014, Texas) for meta-analyses. We used random-effects meta-
analyses to estimate the proportion of each serotype with the
number of isolates serotyped as the denominator, using the
DerSimonian and Laird method for pooled proportion estimates
with 95% confidence intervals [41]. Pooled estimates for each ser-
otype were then transformed to percentages (pooled percentages)
and adjusted (scaled up or down) to fit 100% for the total of all ser-
otypes (adjusted percentages).
For each at-risk population group, we calculated proportions of
six major clonal complexes (CC1, CC10, CC17, CC19, CC23 and
CC12), of six surface proteins (alp1, alp2, alp3, alp4, alpha C and
rib), and the three pilus islands alleles (PI-1, PI-2a, PI2b). Within
reported CCs, surface proteins and pilus islands, we analysed ten
serotypes distribution. We undertook ameta-analysis for ST17 pro-
portion reported for each at-risk population group.
Regarding time trend analysis, studies were classified according
to median year the samples were taken, into 4 time periods: pre-
2001, 2001 to 2006, 2007 to 2012, and 2013 to 2018. Sensitivity
analyses were done to assess significant changes in serotype distri-
bution when excluding studies that only tested/reported < 5
serotypes.3. Results
3.1. Data included
The total number of studies included in this review (and the
corresponding number of isolates reported) were: 124
(n = 17,427 isolates) for maternal colonisation, 6 (n = 321 isolates)
for maternal invasive GBS disease, 4 (n = 34 isolates) for stillbirth,
including two studies from unpublished dataset obtained from
investigators (QB and GK), 53 (n = 8,940 isolates) for infant GBS
disease, and 11 (n = 2,525 isolates) for adults age 60 and older
(Fig. 1). Six studies reported serotypes for neonatal sepsis/bacter-
aemia cases (n = 623 isolates) and meningitis cases (n = 180 iso-
lates) [42–47]. For MLST and surface protein genes, 78 studies
(n = 7193 isolates) were included in descriptive analysis. Details
from data abstracted are described in supplementary Table S4
and S5. We found 198 studies with data on capsular serotypes of
GBS strains and 78 studies that characterised sequence types, clo-
nal complexes or virulence genes by polymerase chain reaction
(PCR) (Fig. 2). Serotyping methods used were: serological methods
(58%), PCR (24%), and latex agglutination accompanied by PCR
(11%).view of Group B Streptococcal capsular types, sequence types and surface
cine.2020.08.052
Fig. 1. Data search and included studies on group B Streptococcus: A. serotypes for maternal colonisation, B. serotypes for infant invasive disease, C. serotypes for maternal
invasive GBS disease, D. serotypes for GBS- associated stillbirth, E. serotypes for streptococcal invasive disease in the elderly, F. MLST data, and G. virulence proteins. * Papers
from both protein and MLST searches were combined for analysis.
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Fig. 1 (continued)
Fig. 2. Characterisation methods used for description and investigation of GBS strains.
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Fig. 3. A. Distribution worldwide of GBS serotypes by risk population group, B. distribution of GBS serotypes by regions from maternal colonisation isolates (n = 17427), C.
distribution of GBS serotypes by regions from infant invasive disease and stillbirth isolates (n = 8974), D. distribution of GBS serotypes by regions from invasive disease in
elderly population isolates (n = 2525). Results are of adjusted percentages. Size of pie charts correspond to number of isolates from each region. Scale of pie charts not the
same between figures B, C and D.
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In total, 41% of GBS serotype data came from Europe and north-
ern America (81/198). Data from eastern Asia (36/198), sub-
Saharan Africa (27/198), Latin America and the Caribbean
(17/198), and south/south-eastern Asia (15/198) each repre-
sented<18% of the reported studies. The country with the most
studies was China (n = 14), mainly from more recent years
(10/14 in last 10 years), followed by USA, then Canada
(11and10studies,respectively).
Regional variation was observed in data availability by at-risk
population groups. Maternal colonisation data were available in
almost all regions (except Oceania and central Asia) (Supplemen-
tary Fig. S1). There were no other infant invasive disease studies
reporting serotypes from southern Asia which accounts for almost
half the world’s births (Supplementary Fig. S2). Studies reporting
early and late onset infant sepsis and meningitis serotypes were
only from eastern Asia (n = 3) and Europe (n = 3). Isolates causing
maternal invasive disease were reported only from northern Amer-
ica and one study from China (Supplementary Fig. S3). The four
studies with data for GBS-associated stillbirth were from Kenya,
Mozambique, South Africa and Canada (Supplementary Fig. S4).
For older adults, all data were from Europe and northern America,
except for two studies from south-eastern Asia (both from Malay-
sia), and one study from Latin America (Argentina) (Supplementary
Fig. S5).
Regarding virulence proteins and MLST by PCR and/or limited
sequencing, around 45% (35/78) came from Europe, other regions
were eastern Asia 29% (23/78), sub-Saharan Africa 9% (7/78),
northern America 9% (7/78), and western Asia 3% (2/78). One study
each from Latin America and the Caribbean, northern Africa, Aus-
tralia, and southern Asia. (Supplementary Fig. S6).
3.3. Results of GBS serotypes, MLST and virulence proteins data by at-
risk population group
1. Maternal colonisation (n = 17,427 isolates): The most com-
mon GBS serotype globally was serotype III with 25% (95%CI: 23–
27), then serotype Ia with 19% (95%CI: 17–21) (Fig. 3A). Serotype
distribution varied by region (Fig. 3B). Serotypes III, Ia and V were
the three most common serotypes in several regions (Europe and
northern America, eastern Asia, southern, eastern/central Africa,
and Australia/ New Zealand). Serotype III was less common in Latin
America and the Caribbean, south-eastern Asia, southern Asia, and
western Africa, with 11% (95%CI :6–17), 11% (95%CI: 6–17), 11%
(95%CI: 6–15), and 13% (95%CI: 8–18), respectively. Serotype IV
was more common in Europe and northern America with 4%
(95%CI: 3–6) (n = 325/6,659), and in southern Africa with 3%
(95%CI: 2–5) (n = 64/1,897) than other regions (Supplementary
Fig. S7&S8). Serotypes VI-IX were rare in Europe and northern
America (1% (95%CI: 0–2), but in south-eastern Asia, eastern Asia,
southern Asia, and western Africa (with most data from a Ghanaian
study n = 83) [48] they were more common at 16% (95%CI: 6–29),
11% (95%CI: 4–19), 6% (95%CI: 1–15), and 15% (95%CI: 0–83),
respectively.
Twenty-six studies described GBS maternal colonisation by
MLST or virulence proteins (n = 4,019 isolates). CC19 was the most
common clonal complex reported for maternal colonisation with
22%, followed by 19% CC23, 17% CC1, and 15% CC17. Within these
clonal complexes the most common serotype was III representing
98% of CC17 strains and 70% of CC19, while serotype Ia predomi-
nated in CC23 with 65% and serotype V in CC1 with 52% (Supple-
mentary Fig. S9). The pooled proportion of ST17 for maternal
colonisation isolates was 9% (95%CI: 6–13).
Forty percent of maternal colonisation strains had Rib protein
gene, from which 66% were serotype III (66%). Alpha C was alsoPlease cite this article as: F. Bianchi-Jassir, P. Paul, K. N. To et al., Systematic re
proteins as potential vaccine candidates, Vaccine, https://doi.org/10.1016/j.vacreported on 28% of strains and alp1/epsilon on 26% of strains, of
which 59% were serotype Ia (Supplementary Fig. S10). 87% of
strains had at least one of alp 1, alp2/3, alpha C or Rib protein tar-
gets. The combination of PI-1 and PI-2a predominated among
maternal colonisation strains with 38%, followed by only PI-2a in
32%. The biggest proportions of serotypes with pilus island protein
genes were serotype Ia at 69% (PI-2a only) and serotype III at 85%
of strains (PI-1 and PI-2b) (Supplementary Fig. S11).
Newborn/Infant colonisation (n = 159 isolates): Similar to
maternal colonisation, CC19 was the commonest clonal complex
identified with 39%, followed by CC23 with 23%, but less CC17 than
maternal colonisation with only 5%. 60% of CC19 strains expressed
the serotype III CPS and 52% of CC23 strains expressed Ia CPS (Sup-
plementary Fig. S9). The pooled proportion of ST17 for infant
colonisation isolates was 4% (95%CI: 0–11). Different from mater-
nal colonisation, the most common surface proteins genes were
alp 1/epsilon and alp2/alp3 with 27% each, followed by Rib with
23%, and alpha C (18%). 90% of strains with the Rib protein gene
and 92% of strains with alp2/alp3 belonged to serotype III (Supple-
mentary Fig. S10). 97% of the strains had at least one of alp1,
alp2/3, alpha C or rib protein targets. There was only one study
(n = 35) of pilus island protein genes from infant colonisation,
showing 77% had PI-1 and PI-2a, followed by 14% strains with only
PI-2a.
2. Maternal invasive GBS disease (n = 321 isolates): The most
common disease-associated serotype was Ia accounting for 27%
(95%CI: 22–33) of cases, followed by serotype III with 26% (95%
CI: 20–32) and V 17% (95%CI: 10–27) (Fig. 3A). Noting only one
study from eastern Asia (n = 11 isolates) [44], the main difference
with northern America was more serotypes III and V and less ser-
otype Ia, in eastern Asia (Supplementary Fig. S12).
MLST data for maternal disease were available from only one
study (n = 29 isolates) [49], reporting the commonest clonal com-
plex as CC23 (41%) followed by CC17 (24%), where 83% of CC23
were serotype Ia and 86% of CC17 were serotype III (Supplemen-
tary Fig. S13). This study did not specify the number of strains that
were ST17 or report surface proteins or pilus islands data.
3. Infant invasive GBS disease (n = 8,940 isolates): In EOGBS
(n = 4,296) and LOGBS (n = 3,849), serotype III was the most com-
mon with 46% (95%CI: 42–51) and 70% (95%CI: 64–75) of disease
associated with this serotype, respectively. Serotype Ia was the
second most frequently detected serotype in both EOGBS and
LOGBS, with 20% (95%CI: 17–22) and 12% (95%CI: 10–15), respec-
tively. For meningitis cases there was a similar distribution of ser-
otypes between EOGBS and LOGBS (Table 1), with serotype III
predominating with 78% (95%CI: 58–94) and 82% (95%CI: 74–89),
respectively. In sepsis/bacteraemia cases, serotype distribution
varied more in EOGBS than in LOGBS, with more EOGBS cases
caused by serotypes II, V and VI-IX.
Fig. 3C shows geographical distribution of serotypes for infant
GBS disease (0-89daysonset) and GBS-associated stillbirth isolates
all together. A similar serotype distribution is seen in most regions
(7/8), with serotype III ranging from 41% (95%CI: 36–46) in Aus-
tralia/New Zealand (n = 365) to 79% (95%CI: 54–97) in eastern
Africa (n = 112) (Supplementary Fig. S14&S15).
GBS disease in infants had 49 studies reporting MLST and/or vir-
ulence proteins data (n = 3995 isolates). CC17 (42%) was the com-
monest clonal complex. In contrast to infant colonising strains
CC19 and CC23 accounted for only 18% and 15% of infant disease
respectively. ST17 associated with infant invasive disease was
41% (95%CI: 35–47). ST17 was more associated with LOGBS (69%
(234/337)) than EOGBS (30% (101/337)) (Supplementary
Table S6) [22,25,27,44,50–57].
Rib was the surface protein gene most likely to be reported in
infant invasive disease (54%), particularly strains belonging to ser-
otype III (95%) (Supplementary Fig. S16). Other proteins genes inview of Group B Streptococcal capsular types, sequence types and surface
cine.2020.08.052
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Please cite this article as: F. Bianchi-Jassir, P. Paul, K. N. To et al., Systematic re
proteins as potential vaccine candidates, Vaccine, https://doi.org/10.1016/j.vacinfant invasive disease strains were alp1/epsilon with 17%, alpha C
16%, and alp2 and alp3 8% (61/754). 93% of the strains had at least
one of alp1, alp2/3, alpha C or Rib protein targets. The combination
of PI-1 and PI-2b was common in infant invasive strains (46%),
from which 97% were serotype III, followed by the combination
of PI-1 and PI-2a with 32% (Supplementary Fig. S17). HvgA pres-
ence was analysed in six studies [22,25,58–60], all of which were
present in ST17 strains, and was associated with infant disease.
4. GBS-associated stillbirth (n = 34 isolates): Serotypes III and V
were both the most frequently reported with 34% (95%CI: 17–53)
and 24% (95%CI: 9–42), respectively (Fig. 3A). There were no data
on GBS strains using MLST or WGS for stillbirth-associated GBS.
5. Invasive GBS disease in older adults (n = 2525 isolates): Ser-
otype V was the most common with 25% (95%CI: 20–31) followed
by serotype Ia with 23% (95%CI: 19–27), and serotype III 11% (95%
CI:9–14) (Fig. 3A). Fig. 3D shows differences between regions in the
distribution of GBS serotypes in the elderly population, though
Latin America and the Caribbean results are based on one study
(n = 9) and south-eastern Asia on two (n = 16). Nonetheless, in
south-eastern Asia, similar to maternal colonisation (the only other
risk group that has data from this region), serotypes VI to IX have a
higher presence than in other regions, representing 31% (95%CI: 9–
57) of the isolates (4 serotype VI and 1 serotype VII). In Europe and
northern America and in south-eastern Asia invasive disease in the
elderly was caused less by serotype III, compared to invasive dis-
ease in the infant, mother or stillborn infant.
MLST and/or virulence protein data were reported in 17 studies
(n = 2,108 isolates) for adult invasive disease (18 years). Com-
monest CCs were CC1 (37%), being mostly serotypes V (39%) and
Ib isolates (23%); CC23 (18%), with most of the strains belonging
to serotype Ia (90%), and CC10 (18%) of which 84% were serotype
Ib (Supplementary Fig. S13). The proportion of strains reported to
belong to ST17 was 4% (95%CI: 2–6). Adult invasive strains had
mostly alp3 protein gene (29%), alpha C (25%), and Rib (23%). The
majority of strains with alp3 gene were serotype V (82%), while
those with Rib were mostly serotype III (72%) (Supplementary
Fig. S16). 99% of strains had at least one of alp1, alp2/3, alpha C
or Rib protein targets. High prevalence was found of the combina-
tion of pilus islands PI-1 and PI-2a (61%), and strains with only PI-
2a (30%). Strains with pilus island proteins genes most commonly
belonged to serotypes V (29%) and Ia (72%) (Supplementary
Fig. S17).3.4. Time trends for GBS serotypes
There has been an increase in the number of studies published
on GBS serotypes in the last twenty years from 17 studies in pre-
2001 to 93 studies in 2013–2018, especially for maternal colonisa-
tion and infant GBS disease in the last period. Although the major-
ity of studies and isolates were from countries in the UN classified
developed region [40], over time, the number of studies from all
other regions have been increasing, to the point that in the last
time period, there were more published studies from countries in
other regions than from the developed region.
Only seven studies, three for maternal colonisation and four for
infant invasive disease, presented longitudinal data for serotype
distribution changes over time [55,61–66]. In general, all studies
described serotype variation over time but usually among the most
common serotypes, for example in a South African study for infant
invasive disease there were changes over a 10-year period with
serotype Ia and III interchanging as the dominant serotypes for
infant invasive disease [64]. Fig. 4 shows the distribution of GBS
serotypes over the past decades according to the study periods of
data collection (samples taken), for maternal colonisation, EOGBS
and LOGBS.view of Group B Streptococcal capsular types, sequence types and surface
cine.2020.08.052
Fig. 4. Time variation of GBS serotypes (adjusted percentages with confidence intervals) for maternal colonisation, early-onset GBS disease and late-onset GBS disease
isolates for countries in the developed region and countries from all other regions.
F. Bianchi-Jassir et al. / Vaccine xxx (xxxx) xxx 9Maternal colonisation: There was limited variation of serotype
distribution through time in the developed region for serotypes III,
V, Ia, Ib and II. However, there was a trend upwards for serotype IV,
which showed a trend of increasing from 1% (95%CI: 0–3) pre-2001
(n = 28/1,440 isolates) to 3% (95%CI: 0–7) in 2001–2006
(n = 77/1,340 isolates), to 5% (95%CI: 3–7) in 2007–2012
(n = 197/3,556 isolates), to 7% (95%CI: 5–10) in 2013–2018
(n = 27/359). Non-typeable serotypes declined from 7% (95%CI:
4–12) in pre-2001, to 2% (95%CI: 0–5) in 2001–2006, to 1% (95%
CI: 0–2) in 2007–2012, to 0% (95%CI: 0–2) in 2013–2018. In all
other regions, serotypes Ia and Ib have reduced from 33% (95%CI:
22–44) in pre-2001 to 16% (95%CI: 10–24) in 2013–2018, and from
10% (95%CI: 6–15) in 2001–2006 to 5% (95%CI: 3–8) in 2013–2018,
respectively. While serotypes III, V and VI-IX have been increasing
(Fig. 4).
Infant invasive disease (EOGBS and LOGBS): For EOGBS, in all
other regions apart from developed region, there was a substantial
increase in disease caused by serotype III in the period 2013–2018,
from 46% (95%CI: 32–61) in pre-2001 to 69% (95%CI: 55–82) inPlease cite this article as: F. Bianchi-Jassir, P. Paul, K. N. To et al., Systematic re
proteins as potential vaccine candidates, Vaccine, https://doi.org/10.1016/j.vac2013–2018. The rest of serotypes maintained a similar proportion
through time or were fluctuating between time periods with no
specific trend, for both the developed region and all other regions.
For LOGBS serotypes fluctuate between time periods with no speci-
fic trends, always with serotype III predominating.3.5. Sensitivity analysis
There were no differences between the serotype proportions of
the main analysis (n = 198 studies) and the sensitivity analysis that
excluded studies sampling or reporting only five or less serotypes
(n = 161 studies) (Supplementary Fig. S18).4. Discussion
This paper provides the most comprehensive worldwide review
of GBS circulating serotypes, and the first systematic review, to our
knowledge, on MLST data and proposed vaccine candidate pro-view of Group B Streptococcal capsular types, sequence types and surface
cine.2020.08.052
10 F. Bianchi-Jassir et al. / Vaccine xxx (xxxx) xxxteins, which is timely given likely investments in GBS vaccines. A
GBS maternal vaccine if effective would reduce invasive disease
after birth (the target of IAP) but also reduce a major burden of
stillbirths, maternal bacteremias, and LOGBS, where IAP is not
expected to be effective. Additionally, most of the current burden
is in LMIC (notably Africa and South Asia) where IAP is unlikely
to be feasible to scale equitably. Our review considers all the rele-
vant at-risk populations: in addition to the previous review of GBS
serotypes for colonised pregnant women, early and late onset
infant sepsis and meningitis, and maternal invasive disease,
[5,37,38] we include stillbirths, which are often omitted, despite
2.6 million annually most of which are preventable [67]. We also
included adults > 60 years.
Our top finding is that a hexavalent polysaccharide–protein
conjugate vaccine (Ia, Ib, II, III, IV, V) has the potential to prevent
up to 93% of worldwide maternal colonising isolates, 95% of mater-
nal invasive GBS disease, 99% of GBS-associated stillbirth, and 99%
of infant invasive GBS disease. Although evidence is still limited, a
vaccine targeting maternal colonisation could provide additional
protection against neonatal disease, and evaluation of this should
be included in phase 2 studies. For maternal colonisation and
maternal disease, the main serotypes across all regions were sim-
ilar: Ia, III, and V. In EOGBS and LOGBS, serotype III dominated with
52% and 77%, respectively. An additional two serotypes (Ia, II)
accounted for more than 15% of infant disease in the Americas, Eur-
ope, and East Asia, while serotypes Ia and V accounted for more
than 20% of infant disease in Sub-Saharan Africa and Australia.
Elderly adult population was included for the first time, provid-
ing a novel picture of the circulating serotypes of GBS causing
infection, and may inform potential benefit of including this at-
risk group in use of a GBS vaccine. The commonest serotypes were
V and Ia, accounting for nearly half of the disease in this popula-
tions, and fewer (14%) serotype III. Hence, a hexavalent vaccine
could prevent up to 96% elderly invasive disease. We note that data
were mainly from northern America and China.
MLST data were reported in only a quarter of the studies
reviewed and even fewer (<5%) includedWGS data. ST17 was more
common in infant invasive disease, and although most ST17 iso-
lates are serotype III, invasiveness of ST17 is independent of the
capsular serotype [56]. It is clear that ST17 strains must be covered
by any GBS vaccine candidate. Thus, sequence types, CC, and viru-
lence factors associated with disease, add more targeted informa-
tion rather than just the capsular polysaccharide. Additionally,
analysis of the genotype through WGS may explore genetic recom-
bination events such as capsular switching and mutations allowing
GBS to become more virulent, which allows better observation of
the potential bacterial population changes during and post-
vaccine implementation. Serotype replacement and serotype
switching following vaccination is a known limitation of the use
of polysaccharide-protein conjugate vaccine. Evidence has sug-
gested that GBS could undergo capsular switching through hori-
zontal transfer of the capsular locus [22,58,68], notably within
CC17 where serotype III strains switched to express serotype IV
capsule. Lopes et al., also studied such an event in an ST1 strain
switching from serotype V to Ib capsule [69]. Capsular switching
in GBS may still be a rare occurrence, yet an introduction of capsu-
lar serotype-based vaccines could create a greater selection pres-
sure leading to serotype replacement in disease as seen with
childhood pneumococcal conjugate vaccine (PCV) immunisation
[70], specifically an increase in non-vaccine serotypes.
Although our results suggest that serotypes (VI to IX) currently
not part of a vaccine represent around 4% of maternal colonisation
isolates worldwide, in south-eastern Asia, eastern Asia, and south-
ern Asia, they represent 20%, 12% and 7%, respectively. In specific
countries such as Japan, a higher prevalence of less common sero-Please cite this article as: F. Bianchi-Jassir, P. Paul, K. N. To et al., Systematic re
proteins as potential vaccine candidates, Vaccine, https://doi.org/10.1016/j.vactypes VI-IX has been reported [62,71–75]. We calculated a pooled
39% (95%CI:25–53) of maternal colonisation isolates as serotypes
VI-IX (from 5 studies, n = 728 isolates) [62,71–74]. However, we
found these serotypes to be less frequently reported as causing inva-
sive disease in infants, with 8% (95%CI:2–15) of EOGBS (4studies)
[75–78], and 1% (95%CI:0–3) of LOGBS (3studies) [75,77–78], while
serotype III still predominates in these cases with 38% (95%CI:26–
51) in EOGBS and 36% (95%CI:3–79) in LOGBS. Protein vaccines
could theoretically reduce the risk of serotype replacement that the-
oretically exists for GBS capsular-polysaccharide based vaccines.
Protein antigen-based vaccines against GBS could provide an
alternative to the multivalent polysaccharide-protein conjugate
vaccines. Based on our findings, a protein-alum adjuvant vaccine,
which contains the alp family surface proteins (alp1/epsilon,
alp2/3, alpha C and Rib), has the potential to prevent up to 87%
of maternal colonisation, 99% of adult invasive disease and 93%
infant invasive disease (percentages of isolates with at least one
of the four protein targets). In addition to the alp protein-based
vaccines, the pilus proteins have been proposed as potential vac-
cine candidates, albeit with conflicting data on whether it has
potential as a vaccine candidate [31,79]. Our findings require con-
firmation from ongoing seroepidemiological studies.
A strength of our review is containing serotype data for many
countries (n = 62), including published and unpublished data, with
notably increasing data from China, South Africa, and Iran. Addi-
tionally, the large number of studies (n = 198) and isolates
(n = 29,247) spanning 20-years allowed us to compare serotype
distribution by developed and other regions, to try to mitigate
potential bias due to specific geographical mix of countries in each
time period, whilst examining time trends.
Time trends however should be interpreted carefully as it is
uncertain if the reported changes in proportions are due to one ser-
otype becoming less/more common or if the changes are relative to
other serotype changes or capture, since differences in proportions
are due to different denominators. Longitudinal studies in a single
population have shown fluctuations but mainly between dominant
serotypes [64]. Changes in serotyping methods, such as an increase
in the use of molecular methods (PCR and sequencing) with time,
could also bias the trend analysis. PCR and sequencing use genetic
targets to identify serotypes, hence GBS that either do not have a
capsule or have a poorly expressed capsule can now be serotyped.
Studies that used molecular methods had lower percentage of non-
typeable strains (supplementary Table S7). Methodological
changes could explain apparent reduction of non-typeable isolates
over time, as PCR and sequencing use increased in the period
2013–2018 compared to previous periods. Additionally, time per-
iod classification was by years of data collection, but the literature
search for maternal colonisation studies from developed countries
and for infant disease studies was limited to publications after the
year 2000, for reason previously explained [5,37], which could
introduce some bias for results pre-2001 for developed countries.
Another important limitation are data gaps for some regions.
Although we were able to increase the geographical representation
compared to our last review [5,37,36], there is still a paucity of data
especially on invasive disease from southern Asia. However, data
from maternal colonisation isolates from Asia can give some
insight into circulating GBS serotypes, although these are not nec-
essarily the same dominant serotypes as those in invasive infant
disease [80]. There are important data gaps for some population
groups, notably stillbirths, maternal invasive disease and
adults > 60 yrs. Most data came from developed regions. For exam-
ple, results for maternal invasive disease were mainly from the
USA (4/6 studies), where the most common maternal colonising
serotype is Ia. Protein expression was limited to few studies and
these may therefore not be representative of the global situation.view of Group B Streptococcal capsular types, sequence types and surface
cine.2020.08.052
F. Bianchi-Jassir et al. / Vaccine xxx (xxxx) xxx 115. Conclusion
GBS contributes a large burden of neonatal and infant disease,
particularly in low- and middle-income countries (LMIC), yet GBS
disease also has an under-recognised burden among pregnant/-
postnatal women and stillbirths, as well as the elderly. Access to
IAP is low in LMIC, where maternal vaccination strategies may be
a high impact, is a more feasible alternative [11]. More studies
on GBS strains to inform vaccine developers are needed to fill in
the data gaps, especially LMIC and for neglected, populations such
as stillbirths. MLST/WGS data help inform which ST/CC and pro-
teins are causing disease and add value beyond considering the
serotype alone. Regular systematic compilation of data on GBS
cases, serotypes and sequence types are needed, ideally embedded
in routine systems for perinatal outcomes. These data are impor-
tant to guide vaccine development, but improved routine data
monitoring post-vaccine licensure will be key to ensure progress
for the poorest, who are currently most likely to be left uncounted.Summary
Group B Streptococcus (GBS) maternal carriage affects an esti-
mated 21 million women worldwide with several GBS vaccines
in development. We summarise data regarding serotypes,
sequence types and virulence markers to inform vaccine design
and implementation, considering at-risk populations, geographical
variations and time trends.Funding
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